AR080818A1 - Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanos - Google Patents

Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanos

Info

Publication number
AR080818A1
AR080818A1 ARP110101094A ARP110101094A AR080818A1 AR 080818 A1 AR080818 A1 AR 080818A1 AR P110101094 A ARP110101094 A AR P110101094A AR P110101094 A ARP110101094 A AR P110101094A AR 080818 A1 AR080818 A1 AR 080818A1
Authority
AR
Argentina
Prior art keywords
cytoskeleton
agent
composition according
peptides
vimentin
Prior art date
Application number
ARP110101094A
Other languages
English (en)
Inventor
Ortega Celia Berta Fernandez
Suarez Anana Caridys Ramirez
Casanovas Dionea Casillas
Guerrero Taimi Emelia Paneque
Gomez Raimundo Ubieta
Echeverria Marta Dubet
Leyva Leonor Margarita Navea
Serra Lila Rosa Castellanos
Cano Carlos A Duarte
Cama Viviana Falcon
Acosta Osvaldo Reyes
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR080818A1 publication Critical patent/AR080818A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

Un método para inhibir la replicacion del virus de la inmunodeficiencia humana (VIH) mediante la modulacion negativa o alteracion del citoesqueleto, específicamente de proteínas que forman parte de los filamentos intermedios del citoesqueleto, más específicamente de las proteínas vimentina y/o queratina-10. La intervencion sobre la estructura de estas proteínas causa una inhibicion de la replicacion del virus en células humanas. Además el uso de agentes, que comprenden péptidos y/o ARN interferentes y/o compuestos lipídicos, y producen la modulacion negativa o alteracion del citoesqueleto celular, para prevenir o tratar la infeccion por el VIH. Medios y métodos para alterar la estructura del citoesqueleto/filamento de la célula, lo que interfiere con la infeccion por VIH de las células humanas y que puede incluso ser inhibida completamente. El citoesqueleto es alterado al reducir la cantidad de vimentina y/o queratina-10 (por ejemplo, por control transcripcional utilizando ARN interferentes) o mediante el uso de péptidos que alteran el citoesqueleto. Reivindicacion 22: Una composicion farmacéutica para la prevencion o el tratamiento de la infeccion por el VIH que comprende un agente que altera los FI del citoesqueleto y un vehículo o excipiente farmacéuticamente aceptable. Reivindicacion 23: La composicion de acuerdo a la reivindicacion 22 donde dicho agente se selecciona del grupo compuesto por polipéptidos, péptidos, ácidos nucleicos y compuestos químicos que alteran los FI. Reivindicacion 24: La composicion de acuerdo a la reivindicacion 23 donde dicho agente es un péptido que se selecciona del grupo de los péptidos identificados como SEQ ID Ns:1 a la SEQ ID Ns:10, y homologos de los mismos. Reivindicacion 25: La composicion de acuerdo a la reivindicacion 23 donde dicho agente es un ARN interferente (iRNA) o un oligonucleotido antisentido dirigido a los genes de vimentina y/o de la queratina 10. Reivindicacion 28: La composicion de acuerdo a la reivindicacion 27 donde dicho compuesto lipídico es la prostaglandina ciclopentano 15 deoxy-delta-12.14-PGJ2.
ARP110101094A 2010-04-01 2011-03-31 Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanos AR080818A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2010000056A CU23896B1 (es) 2010-04-01 2010-04-01 Método para inhibir la replicación del vih en células de mamíferos

Publications (1)

Publication Number Publication Date
AR080818A1 true AR080818A1 (es) 2012-05-09

Family

ID=44168763

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101094A AR080818A1 (es) 2010-04-01 2011-03-31 Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanos

Country Status (16)

Country Link
US (4) US9205128B2 (es)
EP (1) EP2554550B1 (es)
JP (2) JP5925759B2 (es)
KR (1) KR101869917B1 (es)
CN (1) CN102884075B (es)
AR (1) AR080818A1 (es)
AU (1) AU2011235369B2 (es)
BR (1) BR112012025092B1 (es)
CA (1) CA2794930C (es)
CU (1) CU23896B1 (es)
ES (1) ES2604702T3 (es)
MX (1) MX2012011424A (es)
MY (1) MY161923A (es)
RU (1) RU2593948C2 (es)
WO (1) WO2011120474A1 (es)
ZA (1) ZA201207761B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102131041B1 (ko) 2013-12-03 2020-07-08 (주)아모레퍼시픽 태양광 차단 기능성 물질 스크리닝 방법 및 태양광 차단 효능 평가 방법
WO2015191874A1 (en) * 2014-06-12 2015-12-17 Children's National Medical Center Generation of broadly-specific, virus-immune cells targeting multiple hiv antigens for preventive and therapeutic use
WO2016200220A1 (ko) * 2015-06-10 2016-12-15 주식회사 이뮨메드 분리된 비멘틴 유래 펩타이드에 특이적으로 결합하는 항체 또는 상기 펩타이드의 결합 단편
WO2016199964A1 (ko) * 2015-06-10 2016-12-15 주식회사 이뮨메드 분리된 비멘틴 유래 펩타이드에 특이적으로 결합하는 항체 또는 상기 펩타이드의 결합 단편
CU20200110A7 (es) * 2020-12-23 2022-08-09 Ct Ingenieria Genetica Biotecnologia Péptidos para el tratamiento de infecciones respiratorias de origen viral

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2128616A1 (en) 1992-01-23 1993-08-05 Gary H. Rhodes Ex vivo gene transfer
EP0915975A2 (en) 1996-07-03 1999-05-19 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6476193B1 (en) * 1998-10-06 2002-11-05 Curagen Corporation NLK1 protein and NLK1 protein complexes
AU771546B2 (en) * 1999-09-01 2004-03-25 Ppd Development, Lp Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
KR100607611B1 (ko) * 2000-08-24 2006-08-02 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US20020160393A1 (en) 2000-12-28 2002-10-31 Symonds Geoffrey P. Double-stranded RNA-mediated gene suppression
JP2005521393A (ja) * 2002-03-20 2005-07-21 マサチューセッツ インスティテュート オブ テクノロジー Ｈｉｖ治療
US7691582B2 (en) * 2002-09-27 2010-04-06 The Regents Of The University Of Michigan Methods of secretory vimentin detection and modulation
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
WO2006111866A2 (en) * 2005-03-08 2006-10-26 Molmed Spa Hiv vif mutants
US20090227518A1 (en) * 2005-12-02 2009-09-10 The Regents Of The University Of Colorado Compositions and methods for treating actin-mediated medical conditions
CU23674A1 (es) 2007-07-31 2011-05-27 Ct Ingenieria Genetica Biotech Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica

Also Published As

Publication number Publication date
AU2011235369A1 (en) 2012-11-01
KR20130027016A (ko) 2013-03-14
CN102884075A (zh) 2013-01-16
JP2016121172A (ja) 2016-07-07
ZA201207761B (en) 2013-06-26
ES2604702T3 (es) 2017-03-08
CA2794930C (en) 2019-05-21
EP2554550A1 (en) 2013-02-06
US20130130971A1 (en) 2013-05-23
CN102884075B (zh) 2018-09-11
JP5925759B2 (ja) 2016-05-25
RU2012146542A (ru) 2014-05-10
US20160129073A1 (en) 2016-05-12
US9205128B2 (en) 2015-12-08
CU20100056A7 (es) 2012-06-21
BR112012025092A2 (pt) 2017-01-10
US20160108404A1 (en) 2016-04-21
WO2011120474A8 (es) 2012-11-15
BR112012025092B1 (pt) 2022-03-22
MX2012011424A (es) 2012-11-06
KR101869917B1 (ko) 2018-06-21
CU23896B1 (es) 2013-05-31
JP2013523662A (ja) 2013-06-17
CA2794930A1 (en) 2011-10-06
WO2011120474A1 (es) 2011-10-06
MY161923A (en) 2017-05-15
JP6230635B2 (ja) 2017-11-15
US10434137B2 (en) 2019-10-08
EP2554550B1 (en) 2016-09-07
WO2011120474A9 (es) 2012-03-22
US20160106810A1 (en) 2016-04-21
AU2011235369B2 (en) 2015-12-24
RU2593948C2 (ru) 2016-08-10

Similar Documents

Publication Publication Date Title
AR080818A1 (es) Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanos
ES2640875T3 (es) Método para la expresión de ARN celular
BR112021012635A2 (pt) Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2
CL2019002167A1 (es) Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.)
PE20210921A1 (es) Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden
PE20211393A1 (es) COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO
PE20130314A1 (es) PORCIONES DE ENLACE A ANTI-C5a CON ALTA ACTIVIDAD DE BLOQUEO
JP2012136542A5 (es)
PE20230684A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa
BR112012011381A2 (pt) composto antiviral anti-senso e método para tratar infecção viral por influenza
UY33311A (es) Fosforamidatos de nucleosidos
RU2014146170A (ru) Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
ES2653992T3 (es) Dianas moleculares para la prevención y/o el tratamiento de la fibrosis, cicatrices hipertróficas o queloides
Xiao et al. Inhibition of highly pathogenic PRRSV replication in MARC-145 cells by artificial microRNAs
BR112018072198A2 (pt) composição compreendendo micrornas, método de preparação de uma composição de célula-tronco restaurada, formulação farmacêutica e kit
Yang et al. Small interfering RNAs targeting the rabies virus nucleoprotein gene
AR123420A1 (es) Inhibidores de dux4 y métodos de uso de estos
PE20230179A1 (es) Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt)
RU2016119354A (ru) Мирнк и их применение в способах и композициях для ингибирования экспрессии гена orai1
AR083445A1 (es) siARN CONTRA LA FIBROSIS
AR074027A1 (es) Inhibicion de replicas de vih y de expresion de p-24 con elf-5a
Chen et al. Ago-2-mediated slicer activity is essential for anti-flaviviral efficacy of RNAi
Duan et al. CCR5 small interfering RNA ameliorated joint inflammation in rats with adjuvant-induced arthritis
ES2675579T3 (es) Dianas moleculares para el tratamiento de heridas, en particular heridas crónicas
CO2021015696A2 (es) Combinación de compuestos activos

Legal Events

Date Code Title Description
FB Suspension of granting procedure